Abbott scrutinizes Sandoz’ Biaxin generics
Executive Summary
Abbott says it will evaluate Sandoz' clarithromycin ANDAs and take "appropriate measures to protect its intellectual property" covering the Biaxin franchise. FDA approved Sandoz' ANDAs for clarithromycin immediate- and extended-release on Aug. 25; the products have not yet launched. Abbott is in patent litigation with several companies to keep Biaxin XL generics off the market, but Sandoz is not part of that litigation. Immediate-release Biaxin generics launched in May upon expiration of Abbott's compound patent...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.